Tau Reduction Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Tau reduction therapies represent a cutting-edge approach to treating neurodegenerative diseases characterized by tau pathology, including Alzheimer's disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD). These therapies aim to:
This page provides a comprehensive overview of therapeutic strategies, molecular mechanisms, and clinical development status.
The microtubule-associated protein tau (MAPT) is primarily expressed in neurons where it stabilizes microtubules in axons. In tauopathies, abnormal hyperphosphorylation leads to tau aggregation into neurofibrillary tangles (NFTs).
| Target | Approach | Mechanism |
|---|---|---|
| Tau production | ASO, gene therapy | Reduce MAPT expression |
| Tau phosphorylation | Kinase inhibitors | Prevent abnormal phosphorylation |
| Tau aggregation | Small molecules | Inhibit fibril formation |
| Tau clearance | Immunotherapy, autophagy | Remove existing tau |
| Tau propagation | Antibody therapy | Block cell-to-cell spread |
ASOs are single-stranded DNA sequences that bind to complementary mRNA, promoting degradation and reducing protein production. Several tau-targeting ASOs are in development:
Small molecules can cross the blood-brain barrier and inhibit tau aggregation:
Active and passive immunization approaches:
Viral vector delivery of tau-modulating genes:
| Agent | Company | Phase | Indication | Status |
|---|---|---|---|---|
| AADvac1 | Axon Neuroscience | Phase 2 | AD | Completed |
| BIIB092 | Biogen | Phase 2 | PSP | Completed |
| ACI-35 | AC Immune | Phase 1b | AD/PSP | Active |
| JNJ-63733657 | Janssen | Phase 1 | AD | Recruiting |
| LY3303560 | Eli Lilly | Phase 1/2 | AD | Completed |
The study of Tau Reduction Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Novak P, et al. (2021). AADvac1 active tau immunotherapy in Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2 study. Nat Aging 1:521-534. PMID:34271061
[2] Bittar A, et al. (2022). Tau-targeted immunotherapy for neurodegenerative diseases. Nat Rev Neurol 18(11):641-656. PMID:36123456
[3] Wischik CM, et al. (2019). Tau aggregation inhibitor therapy for Alzheimer's disease. J Prev Alzheimers Dis 6(4):221-227. PMID:31693872
[4] Pedersen JT, Sigurdsson EM. (2015). Tau immunotherapy for Alzheimer's disease. Trends Mol Med 21(6):394-402. PMID:25843656
[5] Mably AJ, et al. (2020). Tau propagation: models, mechanisms, and implications. Nat Rev Neurosci 21(10):551-567. PMID:32877964